Mesothelioma: closer to the target?
- 1 May 2013
- journal article
- editorial
- Published by Elsevier BV in The Lancet Oncology
- Vol. 14 (6), 448-9
- https://doi.org/10.1016/S1470-2045(13)70139-6
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 studyThe Lancet Oncology, 2013
- A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced AntigenicityMolecular Cancer Therapeutics, 2013
- Mesothelin-Targeted Agents in Clinical Trials and in Preclinical DevelopmentMolecular Cancer Therapeutics, 2012
- Clinical implications of novel activating EGFR mutations in malignant peritoneal mesotheliomaWorld Journal of Surgical Oncology, 2010
- Absence of Mutations in the Epidermal Growth Factor Receptor (EGFR) Kinase Domain in Patients with MesotheliomaJournal of Thoracic Oncology, 2009
- Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group StudyJournal of Clinical Oncology, 2007
- EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesotheliomaLung Cancer, 2006
- EGFR overexpression in malignant pleural mesothelioma: An immunohistochemical and molecular study with clinico-pathological correlationsLung Cancer, 2006
- CommonEGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesotheliomaInternational Journal of Cancer, 2005
- Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group BClinical Cancer Research, 2005